KYTX

4.2802.06%
TV

Tom Van Blarcom

Senior VP & Head of Research

Dr. Tom Van Blarcom, Ph.D., has been a Senior Vice President and Head of Research at Kyverna Therapeutics, Inc. since August 2022. He joined Kyverna Therapeutics, Inc. in August 2022. He has biopharmaceutical industry experience leading research teams which have contributed to multiple chimeric antigen receptor (CAR) T cells and bispecific antibodies currently under clinical evaluation. Dr. Van Blarcom joins Kyverna from Allogene Therapeutics where he most recently served as Executive Director, Head of Protein Engineering and Research Operation; he joined Allogene shortly after the company acquired the allogeneic cell therapy assets from Pfizer. In this role, he contributed to developing the scientific strategy, led cross-functional teams responsible for execution, and oversaw scientific operations. Dr. Van Blarcom also built the Protein Engineering Department that is responsible for protein sciences and technology development and led to co-inventorship on more than fifteen of Allogene's pending or issued patents. Prior to Allogene, Dr. Van Blarcom held several roles of increasing responsibility at Pfizer and was involved in their initial work on allogeneic CAR T cells that is now part of Allogene. He also spent time at Amgen where he began his industry career. His work has resulted in more than twenty peer-reviewed publications. Dr. Van Blarcom received his Ph.D. in chemical engineering from the University of Texas at Austin and a B.S. in chemical engineering from North Carolina State University.

Positions